SEC Filing Summary: Renovaro Inc. (RENB)
Business Context and Reporting Period
This is a Form 8-K Current Report filed by Renovaro Inc. (not Lunai Bioworks Inc.) on April 25, 2024, covering an event dated April 24, 2024. The registrant is a Delaware corporation with principal executive offices in Los Angeles, CA. The filing serves to disseminate a press release issued on April 24, 2024, which is attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to announce the issuance of a press release and does not contain a financial statement or quantitative performance data.
Material Changes
No material financial changes versus prior periods are detailed in this filing. The sole material event reported is the issuance of a press release on April 24, 2024.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in Item 8.01 and Exhibit 99.1 (the press release) is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. Consequently, no specific guidance, outlook, management commentary, risks, or contingencies are disclosed within the body of this 8-K text. Investors must refer to the attached press release for such details.
Investor Verification Checklist
- Verify the content of the press release dated April 24, 2024, provided as Exhibit 99.1, as the 8-K body contains no operational details.
- Confirm the correct registrant name is Renovaro Inc. (RENB), noting the discrepancy with the requested company name "Lunai Bioworks Inc."
- Review the press release for any forward-looking statements, as the 8-K filing itself disclaims liability for the content of the attached exhibit.
- Check subsequent filings for any financial updates if the press release announced significant corporate actions.